Overview

Phase I/2 Study of MHB036C in Participants With Advanced or Metastatic Solid Tumors

Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety, pharmacokinetics, and anti-tumor efficacy of MHB036C in participants with advanced or metastatic solid tumors.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Minghui Pharmaceutical Pty Ltd